Skip to Content

Acrux Ltd ARUXF

Morningstar Rating
$0.03 0.00 (13.07%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ARUXF is trading at a 42% discount.
Price
$0.03
Fair Value
$9.84
Uncertainty
Extreme
1-Star Price
$4.15
5-Star Price
$5.54
Economic Moat
Hwxk
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ARUXF is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.04
Day Range
$0.030.04
52-Week Range
$0.030.05
Bid/Ask
$0.00 / $0.30
Market Cap
$8.86 Mil
Volume/Avg
3,005 / 11,503

Key Statistics

Price/Earnings (Normalized)
Price/Sales
1.16
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
36

Valuation

Metric
ARUXF
Price/Earnings (Normalized)
Price/Book Value
2.31
Price/Sales
1.16
Price/Cash Flow
Price/Earnings
ARUXF

Financial Strength

Metric
ARUXF
Quick Ratio
1.94
Current Ratio
2.09
Interest Coverage
Quick Ratio
ARUXF

Profitability

Metric
ARUXF
Return on Assets (Normalized)
−1.91%
Return on Equity (Normalized)
−3.35%
Return on Invested Capital (Normalized)
−2.53%
Return on Assets
ARUXF
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRDvqylvlrBcjr$570.1 Bil
VRTX
Vertex Pharmaceuticals IncMjnpgqdvqTfkyf$107.8 Bil
REGN
Regeneron Pharmaceuticals IncYgnkzccqZfxjbrh$105.6 Bil
MRNA
Moderna IncRsmsqfrmJmz$40.8 Bil
ARGX
argenx SE ADRBwmpqmxkfTwgx$23.7 Bil
BNTX
BioNTech SE ADRWqkfhrdnyZbtk$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncJcwvrptjxCcwvzv$19.4 Bil
BMRN
Biomarin Pharmaceutical IncWcnqrqqjMrfyjk$16.7 Bil
RPRX
Royalty Pharma PLC Class AFncdqdcvHrpgb$13.6 Bil
INCY
Incyte CorpQrwyjgvCrrbhkg$12.8 Bil

Sponsor Center